Since Clearside Biomedical Inc. (NASDAQ:CLSD) and ARCA biopharma Inc. (NASDAQ:ABIO) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Clearside Biomedical Inc. N/A 591.50 81.61M -2.66 0.00
ARCA biopharma Inc. N/A 0.00 7.93M -0.82 0.00

In table 1 we can see Clearside Biomedical Inc. and ARCA biopharma Inc.’s gross revenue, earnings per share and valuation.


Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Clearside Biomedical Inc. 0.00% -142.5% -102.8%
ARCA biopharma Inc. 0.00% 0% 0%


4.6 and 4.6 are the respective Current Ratio and a Quick Ratio of Clearside Biomedical Inc. Its rival ARCA biopharma Inc.’s Current and Quick Ratios are 8.5 and 8.5 respectively. ARCA biopharma Inc. has a better chance of clearing its pay short and long-term debts than Clearside Biomedical Inc.

Insider & Institutional Ownership

Institutional investors owned 56% of Clearside Biomedical Inc. shares and 15.4% of ARCA biopharma Inc. shares. 13.31% are Clearside Biomedical Inc.’s share owned by insiders. On the other hand, insiders owned about 0.89% of ARCA biopharma Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Clearside Biomedical Inc. -9.09% 18.64% -11.95% -78.63% -80.09% 30.84%
ARCA biopharma Inc. 5.75% 9.55% -15.6% -24.74% -36.11% 37.93%

For the past year Clearside Biomedical Inc.’s stock price has smaller growth than ARCA biopharma Inc.


ARCA biopharma Inc. beats on 6 of the 7 factors Clearside Biomedical Inc.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion (RVO); and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME). The companyÂ’s pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD). Clearside Biomedical, Inc. has a collaboration agreement with Santen Pharmaceutical Co., Ltd. to develop compounds for suprachoroidal space injection that are designed to treat DME, wet AMD, and RVO, as well as to reduce elevated intraocular pressure associated with glaucoma for a sustained period of time. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company’s lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *